3
|
Fersing C, Boudot C, Pedron J, Hutter S, Primas N, Castera-Ducros C, Bourgeade-Delmas S, Sournia-Saquet A, Moreau A, Cohen A, Stigliani JL, Pratviel G, Crozet MD, Wyllie S, Fairlamb A, Valentin A, Rathelot P, Azas N, Courtioux B, Verhaeghe P, Vanelle P. 8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases. Eur J Med Chem 2018; 157:115-126. [PMID: 30092366 PMCID: PMC7089781 DOI: 10.1016/j.ejmech.2018.07.064] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2018] [Revised: 07/26/2018] [Accepted: 07/28/2018] [Indexed: 11/28/2022]
Abstract
Based on a previously identified antileishmanial 6,8-dibromo-3-nitroimidazo[1,2-a]pyridine derivative, a Suzuki-Miyaura coupling reaction at position 8 of the scaffold was studied and optimized from a 8-bromo-6-chloro-3-nitroimidazo[1,2-a]pyridine substrate. Twenty-one original derivatives were prepared, screened in vitro for activity against L. infantum axenic amastigotes and T. brucei brucei trypomastigotes and evaluated for their cytotoxicity on the HepG2 human cell line. Thus, 7 antileishmanial hit compounds were identified, displaying IC50 values in the 1.1-3 μM range. Compounds 13 and 23, the 2 most selective molecules (SI = >18 or >17) were additionally tested on both the promastigote and intramacrophage amastigote stages of L. donovani. The two molecules presented a good activity (IC50 = 1.2-1.3 μM) on the promastigote stage but only molecule 23, bearing a 4-pyridinyl substituent at position 8, was active on the intracellular amastigote stage, with a good IC50 value (2.3 μM), slightly lower than the one of miltefosine (IC50 = 4.3 μM). The antiparasitic screening also revealed 8 antitrypanosomal hit compounds, including 14 and 20, 2 very active (IC50 = 0.04-0.16 μM) and selective (SI = >313 to 550) molecules toward T. brucei brucei, in comparison with drug-candidate fexinidazole (IC50 = 0.6 & SI > 333) or reference drugs suramin and eflornithine (respective IC50 = 0.03 and 13.3 μM). Introducing an aryl moiety at position 8 of the scaffold quite significantly increased the antitrypanosomal activity of the pharmacophore. Antikinetoplastid molecules 13, 14, 20 and 23 were assessed for bioactivation by parasitic nitroreductases (either in L. donovani or in T. brucei brucei), using genetically modified parasite strains that over-express NTRs: all these molecules are substrates of type 1 nitroreductases (NTR1), such as those that are responsible for the bioactivation of fexinidazole. Reduction potentials measured for these 4 hit compounds were higher than that of fexinidazole (-0.83 V), ranging from -0.70 to -0.64 V.
Collapse
Affiliation(s)
- Cyril Fersing
- Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, FAC PHARM, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France
| | - Clotilde Boudot
- Université de Limoges, UMR Inserm 1094, Neuroépidémiologie Tropicale, Faculté de Pharmacie, 2 rue du Dr Marcland, 87025, Limoges, France
| | - Julien Pedron
- LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France
| | - Sébastien Hutter
- IHU Méditerranée Infection, Aix-Marseille Univ, UMR VITROME, 19-21 Boulevard Jean Moulin, 13005, Marseille, France
| | - Nicolas Primas
- Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, FAC PHARM, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France
| | - Caroline Castera-Ducros
- Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, FAC PHARM, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France
| | | | | | - Alain Moreau
- LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France
| | - Anita Cohen
- IHU Méditerranée Infection, Aix-Marseille Univ, UMR VITROME, 19-21 Boulevard Jean Moulin, 13005, Marseille, France
| | | | | | - Maxime D Crozet
- Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, FAC PHARM, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France
| | - Susan Wyllie
- University of Dundee, School of Life Sciences, Division of Biological Chemistry and Drug Discovery, Dow Street, Dundee, DD1 5EH, Scotland, United Kingdom
| | - Alan Fairlamb
- University of Dundee, School of Life Sciences, Division of Biological Chemistry and Drug Discovery, Dow Street, Dundee, DD1 5EH, Scotland, United Kingdom
| | - Alexis Valentin
- UMR 152 PHARMA-DEV, Université de Toulouse, IRD, UPS, Toulouse, France
| | - Pascal Rathelot
- Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, FAC PHARM, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France
| | - Nadine Azas
- IHU Méditerranée Infection, Aix-Marseille Univ, UMR VITROME, 19-21 Boulevard Jean Moulin, 13005, Marseille, France
| | - Bertrand Courtioux
- Université de Limoges, UMR Inserm 1094, Neuroépidémiologie Tropicale, Faculté de Pharmacie, 2 rue du Dr Marcland, 87025, Limoges, France
| | | | - Patrice Vanelle
- Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, FAC PHARM, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France.
| |
Collapse
|